Showing 221-230 of 333 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Enabling studies to advance intra-lymph node depots as a durable antigen-specific immunotherapy for T1D | University of Maryland | Christopher Jewell | Cures | 01-February-2023 to 31-January-2026 | $989.997,00 |
| Engineered Nanoparticles for Beta Cell-Targeted Therapeutics | The University of Chicago | Raghavendra Mirmira | Cures | 01-April-2023 to 31-March-2026 | $897.822,00 |
| Type 1 Diabetes Consortium – New Onset Workstream | Critical Path Institute (C-Path) | Joseph Hedrick | Cures | 28-October-2022 to 31-December-2025 | $1.132.723,00 |
| Determination of autoreactive B lymphocyte development by ROS in T1D | Vanderbilt University Medical Center (VUMC) | Christopher Wilson | Cures | 01-July-2023 to 30-June-2026 | $234.766,00 |
| Tolerance signals from human pregnancy for beta cell replacement therapy | University of Florida | Edward Phelps | Cures | 01-December-2023 to 30-November-2025 | $600.000,00 |
| Development and Preclinical Assessment of a Biovascular Pancreas | Humacyte | Kaleb Naegeli | Cures | 01-April-2023 to 31-March-2026 | $800.000,00 |
| Transcriptional modulation by BET bromodomain inhibitors in beta cells | The Medical College of Wisconsin Inc. | Joshua Nord | Cures | 01-March-2023 to 28-February-2026 | $221.638,00 |
| Novel insulin formulations for pumps | Stanford University | Yanxian Zhang | Improving Lives | 01-March-2023 to 28-February-2026 | $243.986,00 |
| Pancreatic Lymph Node T cell Composition and Function in Human Type 1 Diabetes | Trustees of the University of Pennsylvania | Gregory Golden | Cures | 01-April-2023 to 31-March-2026 | $214.356,00 |
| Defining and applying neo-epitope specific TCRs for engineered cell therapy | Benaroya Research Institute at Virginia Mason | Aïsha Callebaut | Cures | 01-March-2023 to 28-February-2026 | $205.273,00 |